Sanofi and Regeneron to start Phase III lipid-lowering antibody programme
This article was originally published in Scrip
Executive Summary
Sanofi and Regeneron are to begin the first Phase III programme for an investigational drug targeting PCSK9 in the coming weeks. They said the decision to start the global programme for SAR236553/REGN727, a lipid-lowering antibody, "across multiple patient populations" was "based on discussions with the US and European regulatory authorities".